Compare Amgen, Inc. (AMGN) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Invesco Ltd. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Invesco Ltd. trades at $28.79 (market cap $12.85B). The key difference: Amgen, Inc. is far larger — about 15.3× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| AMGN | IVZ | |
|---|---|---|
Market Cap | $196.12B | $12.85B |
Sector | Health | Financials |
52-Week High | $388.16 | $29.44 |
52-Week Low | $271.18 | $16.74 |
Enterprise Value | $241.41B | $23.09B |
Dividend Yield | 2.77% | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IVZ trades at $28.98, up 1.29% today, with a bullish technical signal and analyst consensus price target of $29.79. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, while the company reported a net loss of $281.70 million in 2025. Positive cash flow from operations of $1.53 billion and a recent dividend payment of $0.22 per share highlight financial stability amid profitability challenges.
The outlook for IVZ is cautiously optimistic, supported by strong analyst buy ratings and improving assets under management, but weighed down by negative net income margins and competitive pressures in asset management. Key risks include execution on profitability and market volatility affecting AUM growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
